Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clonal evolution in progressive CLL with subclonal TP53 aberrations treated first-line with ibrutinib
2017-001099-49Phase 2Active
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by IRCCS Ospedale San Raffaele. Started Jun 2021; status: active.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2017-001099-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001099-49.